Sugi Predict

Sugi Predict / Compounds / SCHEMBL2461889

SCHEMBL2461889

SCHEMBL2461889

N[N+]12C=CN=CC1=C(C1=CC=C1)N=C2c1cccc(OCc2ccc(Cl)cc2F)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPD P32754 1/20 0.35
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ DHFR P00374 1/20 0.32
▸ DCPS Q96C86 1/20 0.32
▸ NR4A1 P22736 1/20 0.32
▸ NR4A2 P43354 1/20 0.32
▸ NR4A3 Q92570 1/20 0.32
▸ PTGER1 P34995 4/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ CYP2C9 P11712 2/20 0.31
▸ TBXA2R P21731 2/20 0.31
▸ PTGS1 P23219 2/20 0.31
▸ CYP2C19 P33261 2/20 0.31
▸ PTGER3 P43115 2/20 0.31
▸ PTGER2 P43116 2/20 0.31
▸ NR1H2 P55055 2/20 0.31
▸ INPPL1 O15357 1/20 0.30
▸ MAPK14 Q16539 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460739 0.90 EGFR (0.38) HPDMEN1KMT2A
SCHEMBL2460564 0.88 IGF1R (0.36) DCPSNR1H2
SCHEMBL2463513 0.88 MEN1 (0.46) MEN1KMT2ACYP2C9CYP2C19
SCHEMBL2462400 0.87 IGF1R (0.35) MEN1KMT2ANR1H2
SCHEMBL2460218 0.87 NR4A2 (0.38) MEN1KMT2ANR4A2
SCHEMBL2461458 0.87 MEN1 (0.37) MEN1KMT2ACYP2C9CYP2C19
SCHEMBL2461743 0.86 NR4A2 (0.39) DHFRNR4A2
SCHEMBL2459470 0.86 MEN1 (0.33) MEN1KMT2A
SCHEMBL2459926 0.86 NR1H2 (0.39) MEN1KMT2ANR4A2NR1H2
SCHEMBL2461637 0.86 MEN1 (0.38) MEN1KMT2ACYP2C9CYP2C19NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 HPD 3048/4885MEN1 1004/4885KMT2A 1100/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 HPD 3048/4885MEN1 1004/4885KMT2A 1100/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 HPD 3048/4885MEN1 1004/4885KMT2A 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.